No profile data available.
Inovio Pharmaceuticals, Inc. (INO) is a healthcare company in the additional cancer treatment drugs industry, based in Plymouth Meeting, United States, with about 134 full-time employees.
It reported revenue of $217,756 for fiscal year 2024, down 73.8% from fiscal year 2023, and net income of -$107.25 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $138.78 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of December 4, 2025.
, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Inovio Pharmaceuticals reported $217,756 in revenue for fiscal year 2024, down 73.8% from $832,010 in fiscal year 2023. In Q3 2025 revenue was $0.
$138.78 million as of December 4, 2025.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Compass Therapeutics, Inc. (CMPX), ALX Oncology Holdings Inc. (ALXO), Kazia Therapeutics Limited (KZIA), TuHURA Biosciences, Inc. (HURA).